EPA vs DHA: When Each Omega-3 Outperforms — Mood, Lipids, and Inflammation

Omega-3 supplements are typically labeled by total EPA plus DHA milligrams, which obscures that the two long-chain marine omega-3s have different molecular targets and different trial records. A 2 to 1 EPA-to-DHA ratio is not the same as a 1 to 2 ratio for depression endpoints, and the icosapent-ethyl cardiovascular literature has further highlighted that EPA-only formulations behave differently from mixed products in clinical trials.

Depression: EPA-dominant formulations consistently outperform DHA

A 2011 meta-analysis by Sublette and colleagues of 15 randomized depression trials found that formulations containing at least 60 percent EPA produced significant improvement in depressive symptoms versus placebo, while DHA-predominant supplements did not [1]. The 2019 international expert consensus from the International Society for Nutritional Psychiatry Research recommends pure EPA or EPA-predominant blends with an EPA to DHA ratio of at least 2:1 for major depressive disorder [2]. The mechanism is debated, but EPA appears more readily metabolized to anti-inflammatory eicosanoids and resolvins, while DHA is preferentially incorporated into neuronal membranes.

Triglyceride lowering: both work, EPA-only avoids LDL elevation

At doses of 3 to 4 grams per day, both EPA-only and EPA plus DHA mixtures reduce triglycerides by roughly 25 to 30 percent in hypertriglyceridemic adults [3]. The clinically important difference is that DHA tends to raise LDL cholesterol modestly, while purified EPA does not. This is one reason icosapent ethyl (a prescription EPA-only ethyl ester) was studied for cardiovascular outcomes in REDUCE-IT, which reported a 25 percent relative reduction in major adverse cardiovascular events in statin-treated high-risk adults [4]. The mixed EPA plus DHA STRENGTH trial of carboxylic-acid omega-3 at the same total dose did not replicate the benefit, sharpening debate over whether the difference is EPA dose, DHA antagonism, or mineral-oil-placebo confounding [5].

Pregnancy and infant neurodevelopment: DHA carries the weight

DHA is the dominant omega-3 in the developing fetal brain and retina, and the prenatal evidence base accordingly focuses on DHA. A Cochrane review of long-chain omega-3 supplementation in pregnancy concluded that an extra 200 mg per day of DHA in late pregnancy reduces the risk of early preterm birth and slightly increases birth weight [6]. EPA crosses the placenta but is preferentially retro-converted or beta-oxidized rather than incorporated into fetal phospholipids. For pregnancy, DHA-predominant prenatal formulas reflect this physiology.

Anti-inflammatory effects in chronic disease: both contribute, EPA leads

In rheumatoid arthritis trials, daily 2.7 to 3.5 grams of combined EPA plus DHA reduces tender joint counts and morning stiffness modestly, with stronger effects at the higher EPA fractions [7]. For systemic inflammatory markers including IL-6 and CRP, EPA-only and EPA-dominant supplements produce larger reductions than DHA-only formulations in head-to-head comparisons [8]. DHA appears more effective for endothelial function and may carry a small blood-pressure-lowering effect not seen with EPA alone.

Choosing a ratio in practice

Adults targeting depression, atherogenic dyslipidemia, or post-MI cardioprotection have the strongest case for EPA-dominant supplements at 1 to 2 grams of EPA daily. Pregnant individuals should ensure at least 200 to 300 mg of DHA per day. For general cardiovascular maintenance in healthy adults, the VITAL trial found that a balanced 840 mg per day EPA plus DHA capsule did not reduce major cardiovascular events versus placebo in the primary analysis, although subgroups with low fish intake showed signal [9]. Total dose, ratio, and patient phenotype all matter — the label number labeled "omega-3" is insufficient on its own.